Epstein-Barr virus infection is known to convert resting B lymphocytes into immortal cells that continuously multiply, which leads to posttransplant lymphoproliferative disorder and can evolve to lymphoma and other lymphoproliferative disorders. In a recent study, Japanese researchers discovered the molecular mechanisms of this growth transformation, demonstrating the Epstein-Barr virus induces nucleolar enlargement and increased proliferation in B cells by activating the cancer-related gene IMPDH2.
Findings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obstruction (MBO) provide evidence to inform clinical decision-making in managing this frequent complication in patients with advanced cancer.
Cancer research centers conducting clinical trials could enroll more patients from underrepresented racial and ethnic groups by placing greater emphasis on relieving
Four years ago, a report that a common species of fungus might fuel pancreatic cancer offered a promising new view of the deadly disease.
Using a new approach, Yale Cancer Center researchers at Yale School of Medicine found a new way to substantially improve the effectiveness of CAR-T cell therapy.
A study conducted in the North-East region of Colombia found 11.94% of patients with a high BMI being treated for breast cancer at a regional center experienced heart damage, or cardiotoxicity, during chemotherapy.
University of Pittsburgh researchers have demonstrated how Merkel cell polyomavirus, which causes Merkel cell carcinoma, initiates DNA replication in host cells.
A study by Main Line Health researchers indicates that simultaneously conducting a liquid biopsy and standard tissue biopsy increases the chances of detecting such mutations and is practical for wide usage by hospitals.
In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with Xpovio (selinexor) following systemic therapy may prolong progression-free survival, according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology Plenary Series.
Phase III trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) met their primary endpoints.
